for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

4d Pharma PLC

LBPS.OQ

Latest Trade

6.98USD

Change

0.00(0.00%)

Volume

545

Today's Range

--

 - 

--

52 Week Range

6.02

 - 

15.50

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Latest Developments

4D Pharma PLC - Have Filed Registration Statement Of Which This Prospectus Forms Part With Respect To 22.4 Million Ordinary Shares Held By Shareholders

April 23 (Reuters) - 4D Pharma PLC <DDDD.L>::4D PHARMA PLC - HAVE FILED REGISTRATION STATEMENT OF WHICH THIS PROSPECTUS FORMS PART WITH RESPECT TO 22.4 MILLION ORDINARY SHARES HELD BY SHAREHOLDERS.4D PHARMA PLC - ANY REGISTERED SHARES OFFERED AND SOLD BY REGISTERED HOLDERS ON NASDAQ WILL BE IN THE FORM OF ADSS.4D PHARMA PLC - ANY REGISTERED SHARES OFFERED AND SOLD BY REGISTERED HOLDERS ON AIM WILL BE IN THE FORM OF ORDINARY SHARES.

4D Pharma PLC says collaboration with Parkinson's UK

April 19 (Reuters) - 4D Pharma PLC <DDDD.L>::4D PHARMA PLC - COLLABORATION WITH PARKINSON’S UK.4D PHARMA PLC - 4D PHARMA COLLABORATES WITH PARKINSON'S UK TO ESTABLISH PATIENT ADVISORY BOARD.

4D Pharma FY Diluted Loss/Share 22.8p

April 1 (Reuters) - 4D Pharma PLC <DDDD.L>::FY DILUTED LOSS PER SHARE 22.8 PENCE VERSUS 36.75 PENCE LOSS YEAR AGO.FY ADJUSTED LOSS PER SHARE 22.8 PENCE.4D PHARMA - LIKELY DURATION OF DISRUPTION BY COVID-19 STILL REMAINS UNCERTAIN, DIFFICULT TO ACCURATELY PREDICT IMPACT ON CO OPERATIONS.

4D Pharma To Raise About $24 Mln Via Private Placement

March 17 (Reuters) - 4D Pharma PLC <DDDD.L>::4D PHARMA PLC - 4D PHARMA ANNOUNCES PRIVATE PLACEMENT.4D PHARMA - EXPECTS TO COMPLETE MERGER WITH LONGEVITY ACQUISITION CORP, ITS AMERICAN DEPOSITARY SHARES TO BE ADMITTED TO TRADING ON NASDAQ ON 22 MARCH.4D PHARMA PLC - TO RAISE ABOUT $24.03 MILLION IN A PRIVATE PLACEMENT OF NEW ORDINARY SHARES OF £0.0025 EACH AT $1.53 PER SHARE.

4D Pharma Says John Beck Appointed CFO

March 1 (Reuters) - 4D Pharma PLC <DDDD.L>::4D PHARMA PLC - APPOINTMENT OF JOHN BECK AS CHIEF FINANCIAL OFFICER (CFO).

4D Pharma In Clinical Trial Collaboration With Merck KGaA, Pfizer

Feb 8 (Reuters) - 4D Pharma PLC <DDDD.L>::4D PHARMA PLC - ONCOLOGY CLINICAL COLLABORATION.4D PHARMA PLC - ANNOUNCES CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MERCK KGAA, PFIZER TO EVALUATE MRX0518 IN COMBINATION WITH BAVENCIO.

4D Pharma Announces new positive clinical data from two clinical trials of MRx0518

Nov 9 (Reuters) - 4D Pharma PLC <DDDD.L>::4D PHARMA PLC - SITC DATA MRX0518 MONOTHERAPY AND COMBINATION.4D PHARMA PLC - MRX0518 DEMONSTRATES UPREGULATION OF KEY IMMUNE BIOMARKERS ASSOCIATED WITH ANTI-CANCER ACTIVITY IN NEOADJUVANT MONOTHERAPY SETTING.4D PHARMA - MRX0518 DEMONSTRATES UPREGULATION OF KEY IMMUNE BIOMARKERS ASSOCIATED WITH ANTI-CANCER ACTIVITY IN NEOADJUVANT MONOTHERAPY SETTING.

Longevity Acquisition Corporation Announces Signing Of Definitive Merger Agreement

Oct 22 (Reuters) - Longevity Acquisition Corporation: :LONGEVITY ACQUISITION CORPORATION ANNOUNCES SIGNING OF DEFINITIVE MERGER AGREEMENT.LONGEVITY ACQUISITION - SIGNED A DEFINITIVE MERGER AGREEMENT WITH 4D PHARMA PLC.LONGEVITY ACQUISITION - UPON COMPLETION OF MERGER, SHAREHOLDERS OF LOAC WILL RECEIVE ADSS OF 4D AND LOAC WILL BECOME A WHOLLY-OWNED SUBSIDIARY OF 4D.LONGEVITY ACQUISITION- PER SHARE MERGER CONSIDERATION WILL CONSIST OF 7.5315 ORDINARY SHARES OF 4D PHARMA, PAYABLE IN 4D PHARMA ADSS FOR SHARES OF CO.LONGEVITY ACQUISITION- IT IS ANTICIPATED THAT SHAREHOLDERS OF LOAC PRIOR TO CLOSING WILL COLLECTIVELY OWN ABOUT 13.1% ORDINARY SHARES OF COMBINED CO.

4D Pharma Announces Keytruda Part A Clinical Benefit Data

Aug 26 (Reuters) - 4D Pharma PLC <DDDD.L>::4D PHARMA PLC - MRX0158 KEYTRUDA PART A CLINICAL BENEFIT DATA.4D PHARMA - FOLLOWING SUCCESSFUL COMPLETION OF PART A SAFETY PHASE, PART B COHORT EXPANSION TRIAL IS ENROLLING AT MULTIPLE SITES.

Link Fund Solutions Dissolves Stake In 4D Pharma As Of June 8 Vs Prior Stake Of 11.96%

June 10 (Reuters) - 4D Pharma PLC <DDDD.L>::LINK FUND SOLUTIONS DISSOLVES STAKE IN 4D PHARMA AS OF JUNE 8 VERSUS PRIOR STAKE OF 11.96% - FILING.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up